tiprankstipranks
SK bioscience Co.,Ltd. (KR:302440)
:302440
South Korea Market

SK bioscience Co.,Ltd. (302440) Stock Statistics & Valuation Metrics

Followers

Total Valuation

SK bioscience Co.,Ltd. has a market cap or net worth of ₩2.55T. The enterprise value is $3.17M.
Market Cap₩2.55T
Enterprise Value$3.17M

Share Statistics

SK bioscience Co.,Ltd. has 78,456,550 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding78,456,550
Owned by Insiders
Owned by Institutions

Financial Efficiency

SK bioscience Co.,Ltd.’s return on equity (ROE) is -0.03 and return on invested capital (ROIC) is -3.75%.
Return on Equity (ROE)-0.03
Return on Assets (ROA)-0.02
Return on Invested Capital (ROIC)-3.75%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee661.96M
Profits Per Employee-58.36M
Employee Count984
Asset Turnover0.22
Inventory Turnover3.13

Valuation Ratios

The current PE Ratio of SK bioscience Co.,Ltd. is ―. SK bioscience Co.,Ltd.’s PEG ratio is -25.96.
PE Ratio
PS Ratio5.79
PB Ratio2.11
Price to Fair Value2.11
Price to FCF-46.78
Price to Operating Cash Flow-960.08
PEG Ratio-25.96

Income Statement

In the last 12 months, SK bioscience Co.,Ltd. had revenue of 651.37B and earned -56.17B in profits. Earnings per share was -718.26.
Revenue651.37B
Gross Profit59.49B
Operating Income-151.33B
Pretax Income-85.86B
Net Income-56.17B
EBITDA-60.31B
Earnings Per Share (EPS)-718.26

Cash Flow

In the last 12 months, operating cash flow was -2.77B and capital expenditures -219.07B, giving a free cash flow of -221.84B billion.
Operating Cash Flow-2.77B
Free Cash Flow-221.84B
Free Cash Flow per Share-2.83K

Dividends & Yields

SK bioscience Co.,Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.44
52-Week Price Change-27.54%
50-Day Moving Average
200-Day Moving Average
Relative Strength Index (RSI)
Average Volume (3m)

Important Dates

SK bioscience Co.,Ltd. upcoming earnings date is Aug 10, 2026, TBA (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 10, 2026
Ex-Dividend Date

Financial Position

SK bioscience Co.,Ltd. as a current ratio of 3.82, with Debt / Equity ratio of 30.38%
Current Ratio3.82
Quick Ratio3.24
Debt to Market Cap0.12
Net Debt to EBITDA-6.04
Interest Coverage Ratio-16.10

Taxes

In the past 12 months, SK bioscience Co.,Ltd. has paid -29.69B in taxes.
Income Tax-29.69B
Effective Tax Rate0.35

Enterprise Valuation

SK bioscience Co.,Ltd. EV to EBITDA ratio is -68.54, with an EV/FCF ratio of -51.30.
EV to Sales6.35
EV to EBITDA-68.54
EV to Free Cash Flow-51.30
EV to Operating Cash Flow40.33

Balance Sheet

SK bioscience Co.,Ltd. has ₩890.16B in cash and marketable securities with ₩538.00B in debt, giving a net cash position of ₩352.16B billion.
Cash & Marketable Securities₩890.16B
Total Debt₩538.00B
Net Cash₩352.16B
Net Cash Per Share₩4.49K
Tangible Book Value Per Share₩23.57K

Margins

Gross margin is 6.36%, with operating margin of -23.23%, and net profit margin of -8.62%.
Gross Margin6.36%
Operating Margin-23.23%
Pretax Margin-13.18%
Net Profit Margin-8.62%
EBITDA Margin-9.26%
EBIT Margin-23.23%

Analyst Forecast

The average price target for SK bioscience Co.,Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast66.43%
EPS Growth Forecast-72.93%

Scores

Smart ScoreN/A
AI Score